ANPCY News and Press, Angle Plc Surrey ADR From 05/11/21

Parsortix system harvests intact CTCs for whole genomic sequencing identifying multiple druggable targets Study demonstrates ctDNA and CTCs can both be analysed using the same blood sample GUILDFORD, UK / ACCESSWIRE / May 11, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leadi...

SURREY, UK / ACCESSWIRE / April 30, 2021 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 203,333 new Ordinary shares of £0.10 each ("New Ordinary Shares") in the Company. ...

PATIENT ENROLMENT COMPLETED IN OVARIAN CANCER CLINICAL VERIFICATION STUDY Headline results from the Study expected in Q4 2021 Study designed to support launch of an ovarian cancer test from ANGLE's clinical laboratories in the United States and the UK GUILDFORD, SURREY, UK / ACCE...

Contract Worth Up to US$1.2 Million With Potential for Further Contracts From the Same Customer Parsortix System Being Utilised in Cancer Drug Trials for Liquid Biopsy Longitudinal Monitoring Which Is Not Possible With Tissue Biopsies GUILDFORD, UK / ACCESSWIRE / April 16, 2021 / ...

GUILDFORD, SURREY / ACCESSWIRE / April 15, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2020 on Thursday 29 April 2021. A virtual meeting and webcast for analysts will be held at 10:00...

ANGLE'S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATIONS AT LEADING CANCER CONFERENCE Publication of study results demonstrating the capabilities of two new assays in clinical samples at AACR 2021 Immunotherapy assay enables determination of PD-L1 status in significant proportion...

Delivering on strategy to accelerate commercialisation of the Parsortix system and act as a demonstrator to support product deployment UK and US clinical laboratories now open and ready to provide CTC analysis services and discussions with pharmaceutical industry customers ongoing G...

UPDATE ON SUBMISSION FOR FDA CLEARANCE OF THE PARSORTIX SYSTEM Additional Information Request received from FDA as expected and ANGLE response being prepared in line with expected timescales FDA has indicated its review processes for non COVID-19 devices are currently slower than usu...

CTCS HARVESTED BY PARSORTIX UNCOVER NOVEL METASTATIC BIOMARKER Parsortix system able to harvest difficult-to-detect mesenchymal CTCs Metastatic biomarker Cyr61 found by researchers in 40% of breast cancer CTCs may be a novel therapeutic target in treating drug-resistant breast canc...

Use of Parsortix System Enables a Dynamic Assessment of Patient Response to Treatment in Non-Small Cell Lung Cancer CTCs harvested by the Parsortix system successfully used to measure the dynamic role of EMT and PD-L1 in patient response to therapy Findings support ANGLE's plan...